Trial Profile

Enhanced passive safety surveillance of Vaxigrip (trivalent inactivated split virion influenza vaccine, IM route) and Intanza 15 (trivalent inactivated split virion influenza vaccine, ID route) vaccines in Europe during the influenza season 2015/16

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 19 Jul 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Influenza virus vaccine (Primary) ; Influenza virus vaccine (Primary) ; Influenza virus vaccine (Primary) ; Influenza virus vaccine (Primary)
Indications Influenza virus infections
Focus Adverse reactions
Sponsors sanofi pasteur MSD

13 Jul 2016 Status changed from active, no longer recruiting to completed.
28 Jan 2016 According to United Kingdom Clinical Research Network record, status changed from recruiting to active, no longer recruiting.
27 Nov 2015 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com